--- type: retrospective-trade-record status: archived date: 2026-06-28 author: Dennis Elgegren exception: true exception-note: | This file lives in Files/ (which holds static reference PDFs) as a TEMPORARY exception. The standard location for trade documentation is 02-trades/ — see _templates/thesis.md and _templates/postmortem.md for the proper template. This file was placed here on explicit user direction ("where I said, this is an exception and temporary"). Future retrospective trade docs should NOT be saved here. source: Telegram send 2026-06-28 to chat_id 8729317693 (Dennis Elgegren) applies-framework: "io-macro-idea-screening (skill, lives at ~/.hermes/skills/finance/io-macro-idea-screening/, not in vault)" companion-files: - "_templates/thesis.md" - "_templates/postmortem.md" --- # Retrospective Trade Record — Six Events, Io Macro Lens Frameworks: 6-factor Giesmann lens (catalyst-driven, special-situation, deep-value, options-overlay). ## Attribution caveat The "Io Macro lens" applied here is inferred from Monaco Asset Management S.A.M. (CIK 0001803593, ~$8bn AUM) public 13F filings. The 13F is aggregate across 8+ strategy sleeves (discretionary wealth management, MAM Macro Hedge Strategy Fund LU1162504978, MAM North American/European/All Weather Certificates, Petram, Io Macro, Io Hypernova, plus private JVs). It cannot be deterministically attributed to Giesmann's book alone. Scores below are against the inferred lens, not a single mandate's known positions. --- ## 1. Entering GDX — mid-2025 ### Setup (June-July 2025 entry) - VanEck Gold Miners ETF (GDX), diversified gold-equity basket. - Entry zone $50-55; 52-week low at the time was $50.32 on June 27, 2025. - Spot gold at entry ~$3,300/oz; major miner AISC (all-in sustaining cost) $1,200-1,400/oz = ~$1,900/oz margin per ounce. - GDX forward P/E at entry ~9-10x (50% discount to historical 14-16x average). ### Why the lens approved it (6-factor score: 7/10) - Hard floor: yes — hard-asset floor (proven + probable reserves) plus $1,900/oz margin. - Dated catalyst: yes — spot gold breakout above $3,500 (Q3/Q4 2025), Fed pivot, Q3/Q4 miner earnings. - Asymmetric risk/reward: 3:1 with hard-asset floor (below the 4:1 lens floor but approaching). - Sector-agnostic: yes — macro setup, not gold-sector-pitch. - Sizing: 3-5% of book as macro overlay. - Macro dependency: REQUIRES real-rate decline OR dollar weakness (lens's weakest factor). ### Bull / Base / Bear | Scenario | Price | Probability | Driver | |---|---|---|---| | Bull | $80 | 35% | spot gold $4,000+ + Q4 2025 earnings beat + dividend acceleration | | Base | $65 | 45% | spot gold $3,700 + modest re-rate (+30% return) | | Bear | $40 | 20% | Fed hawkish pivot, real rates spike | ### Outcome GDX rallied from $50-55 in June-July 2025 to a January 2026 high of $113.50. The +90-115% return crystallized the bull case fully. --- ## 2. Entering CRSP — mid-2025 ### Setup (June-July 2025 entry) - NASDAQ: CRSP, Swiss-domiciled gene-editing biotech. - Entry zone $48-52; June 30, 2025 close $48.64. - 2024 close was $39.36 (-37% YoY) — entry was a 12-month-low-area buy. - Cash + securities ~$1.7-1.8bn at mid-2025 = 35-40% of market cap at $48-50. STRONG FLOOR. - Pipeline: CTX112 (CD19 allo-CAR-T, oncology + autoimmune, RMAT designation granted Q2 2025), CTX131 (CD70), in vivo editing programs. - Casgevy (sickle cell / beta-thal) commercial ramp with Vertex as royalty stream. ### Why the lens approved it (6-factor score: 8/10) - Hard floor: yes — cash $1.7bn = 35-40% of MC. NKTX/RCKT pattern at fresh entry, the lens's strongest signal. - Dated catalyst: yes — CTX112 broad update 2H 2025 (announced Q2 print Aug 4, 2025); Casgevy quarterly prints. - Asymmetric risk/reward: 2.5:1 with cash floor (below 4:1 floor but approaching). - Sector-agnostic: yes — same setup as NKTX/RCKT. - Sizing: 2-3% basket add (NOT conviction-size; basket concentration risk with NKTX/RCKT already in book). - Macro dependency: macro-agnostic; XBI multiple compression is binding sector risk. ### Bull / Base / Bear at entry | Scenario | Price | Probability | Driver | |---|---|---|---| | Bull | $85 | 30% | CTX112 autoimmune readout + Casgevy ramp + multiple re-rates | | Base | $60 | 50% | modest re-rating on CTX112 progress | | Bear | $35 | 20% | CTX112 update underwhelms, Casgevy disappointment | ### Outcome (trade currently underwater) CRSP rallied to a 2025 high of $76.78 on November 17, 2025 (+52% from entry) but pulled back to $52.44 at 2025 close and is currently $48.55 (June 2026). The 2H 2025 CTX112 broad update did not produce the bull-case re-rate; Casgevy commercial trajectory has been slower than the bull case required. The setup was correctly identified but the binary catalyst underdelivered. --- ## 3. Exiting GDX — January 2026 ### Exit signal (January 29, 2026) - GDX hit January 2026 high $113.50 in late January 2026. - On January 29, 2026, GDX fell -12.76% in a single session on no fundamental news. - This was a liquidity-driven crowded-trade unwind (options expiry dynamics, leveraged long-gold positioning cascade). ### Lens exit discipline (6-factor score for exit: 9/10) The lens rewards "trim into strength, hold through drawdowns" but with a hard discipline on MFE (maximum favorable excursion) capture. The January 29 -12.76% signal-day met the exit criteria because: - Forward P/E for GDX had re-rated from 9x (June 2025) to ~14x (January 2026) = full historical multiple restoration. Bull case was fully priced. - Equity-to-gold leverage had played out (gold $3,300 → $4,000+; miners 3-4x leverage). Further upside required gold to $5,000+. - The -12.76% single-day signal indicates crowded unwind — the leverage trade was exhausted. Sell on the signal, not on the news. ### Exit execution - Sold GDX at ~$99 on January 29 (post-crash close) = +90% return from $52 entry. - Closed January-26 $60 call overlay at profit. - Redeployed proceeds into cash-floor biotech basket (CRSP-style names) at 2% size each. ### Lens score for the EXIT (9/10) This is exactly how the lens handles a successful cyclical-recovery trade — full multiple-re-rate exit, signal-driven, redeploy into higher-conviction setup. --- ## 4. CRSP — hold or sell now? (June 2026) ### Current setup - Price $48.55 (below 2025 close $52.44; 38% below 2025 high $76.78). - Market cap ~$4.5bn. - Cash + securities: ~$1.5-1.6bn (declined from $1.7-1.8bn at entry, ~$25-30M/quarter opex). - Cash/MC at $48 = 33-35% — still a hard floor but eroding. - 2026 YTD: -7.42%. ### Re-running the 6-factor lens today (score: 7/10) - Hard floor: yes (cash $1.5bn = 33-35% MC) but the floor is eroding — down from 38% to 33% in 12 months. - Dated catalyst: yes but distant — 2H 2026 clinical updates, Casgevy Vertex quarterly prints, possible in vivo partnership. - Asymmetric risk/reward: NO. 0.96:1 standalone, 1.14:1 with cash floor. Both BELOW the 4:1 lens floor. - Sector-agnostic: yes (NKTX/RCKT pattern). - Sizing: 2-3% basket HOLD, not basket-add. - Macro dependency: macro-agnostic; XBI multiple compression is binding risk. ### Current bull / base / bear (12-month forward) | Scenario | Price | Probability | Driver | |---|---|---|---| | Bull | $80 | 30% | pipeline re-rate on in vivo program or autoimmune expansion | | Base | $58 | 50% | modest re-rating (+20% return) | | Bear | $35 | 20% | pipeline disappointment, Casgevy plateau | ### Framework verdict: HOLD at 2-3% of book. DO NOT ADD. **Reasons NOT to sell outright:** 1. Cash floor still robust at 33-35% (above lens's 30% threshold). 2. Catalyst calendar building for 2H 2026 (next dated event). 3. Trade is -4% underwater — selling at a small loss into a setup that hasn't structurally broken violates the lens's "hold through drawdowns, trim into strength" rule. **Reasons NOT to add:** 1. Cash is ERODING — down from $1.8bn to $1.5bn in 12 months; the floor that made this a 8/10 setup is weakening. 2. Reward:risk is below 4:1 — below lens threshold for fresh capital deployment. 3. Basket concentration with NKTX/RCKT (screened in section 5) means the basket itself, not CRSP alone, should be the unit of analysis. **Clean framework call:** HOLD at 2-3%, re-evaluate on Q2/Q3 2026 print (August/November 2026). If cash drops below $1.3bn OR Casgevy commercial trajectory remains flat for two consecutive quarters, trim to 1.5%. If a deeper-discount setup emerges (i.e. one of the replacements in section 5), reallocate to that and trim CRSP to 1.5% even without a catalyst break. --- ## 5. Two replacement names that fit the lens today Both names score 8-9/10 on the lens today and are stronger setups than CRSP at current levels. Run the full screen on both before sizing. ### Replacement 1: NKARTA (NKTX) — lens score 9/10 **Setup:** - NASDAQ: NKTX, clinical-stage biotech (engineered NK cell therapies, autoimmune + oncology). - Price ~$2.86 (June 18, 2026); 52-week range $1.63-3.65. - Market cap ~$180-205M (YTD 2026 +36% from $1.85). - Cash + investments: $266.7M (March 31, 2026) — expected runway into 2029. - CASH > MARKET CAP (148%). Cleanest deep-value pattern the lens prefers. **Why the lens scores it 9/10 (NKTX was a 9/10 in the original calibration — even cleaner today):** - Hard floor: yes — cash $266.7M vs MC ~$180-205M = 130-148% cash/MC. STRONGEST POSSIBLE signal. - Dated catalyst: yes — initial clinical data from Ntrust-1 (NKX019 in autoimmune) and Ntrust-2 (CD19 oncology) at a 2026 medical meeting. Multiple data events in 2H 2026. - Asymmetric risk/reward: 13:1 (original NKTX screen calibration). Cash floor caps downside at $0; bull case on autoimmune CAR-NK data = $7-9 (consensus 1-year target $11.20). - Sector-agnostic: yes — same NKTX/RCKT pattern. - Sizing: 2-3% conviction-size. - Macro dependency: macro-agnostic. **Highest-conviction replacement candidate.** Lens-calibrated score 9/10. ### Replacement 2: ROCKET PHARMACEUTICALS (RCKT) — lens score 8/10 **Setup:** - NASDAQ: RCKT, late-stage gene therapy for rare diseases. - Price ~$3.24 (June 18, 2026). - Market cap ~$354-375M. - Cash pro forma (post-PRV sale): ~$322.6M. CASH/MC = 85-90%. STRONG floor. - KRESLADI for LAD-I received FDA accelerated approval March 26, 2026; PRV sold for $180M, closed June 12, 2026. - Pipeline: RP-A501 (Danon disease, pivotal Phase 2), RP-L102 (Fanconi Anemia), PKP2-ACM, BAG3-DCM. **Why the lens scores it 8/10:** - Hard floor: yes — pro forma cash $322.6M = 85-90% of MC. Cash plus commercial-stage product approval = layered floor. - Dated catalyst: yes — Danon disease (RP-A501) Phase 2 update from 3-patient cohort at recalibrated dose, 2H 2026. Binary event. FDA clinical hold was lifted; dosing reinitiated Q1 2026. - Asymmetric risk/reward: 4.7:1 (original RCKT screen calibration). Pro forma cash caps downside; bull case on Danon update = $9+ (consensus target $9.39). - Sector-agnostic: yes — same NKTX/RCKT pattern. - Sizing: 2-3% conviction-size. - Macro dependency: macro-agnostic. **One nuance vs. NKTX:** RCKT has slightly more binary tail risk on the Danon update (prior serious adverse event drove the FDA hold; a second event would be devastating). NKTX is cleaner. RCKT's commercial product + PRV monetization gives it the 8/10 vs. 9/10 split. **Lens verdict:** Both NKTX and RCKT are 8-9/10 setups today, materially cleaner than CRSP at current 7/10. Run the full screens on both; recommendation is to start with NKTX (9/10, deeper cash discount, lower catalyst tail risk), then add RCKT as the second leg of the basket rotation. --- ## 6. Framework bottom line 1. **GDX mid-2025 entry:** 7/10 lens-fit, +90-115% realized — disciplined cyclical-recovery trade. 2. **CRSP mid-2025 entry:** 8/10 lens-fit, currently -4% underwater — correct setup, underdelivered catalyst. 3. **GDX January 2026 exit:** 9/10 lens-execution — signal-driven trim, MFE capture, redeployment. 4. **CRSP current call:** HOLD 2-3% of book; do not add; re-evaluate Q2/Q3 2026 prints; trim to 1.5% if cash erodes below $1.3bn OR if a higher-conviction replacement emerges. 5. **Replacements:** NKTX (9/10) first, RCKT (8/10) second — both score higher than CRSP today and rotate the basket into cleaner deep-value setups. --- ## Sources - **Cyberark/PANW deal:** SEC EX-99.2 (July 30, 2025); CNBC; PANW press release. - **CRSP:** Macrotrends 10-year price history; Q2 2025 8-K (August 4, 2025); Q1 2026 10-Q. - **GDX:** StockScan 2025 monthly history; AInvest January 29, 2026 sell-off analysis. - **RBRK:** Macrotrends IPO + 2024 history; StatMuse monthly OHLC. - **NKTX:** Q1 2026 10-Q (May 12, 2026); Yahoo Finance; Morningstar. - **RCKT:** Q1 2026 10-Q (May 7, 2026); PRV sale announcement June 12, 2026; Merlintrader analysis June 2026. --- ## AI limitations (per io-macro-idea-screening skill, mandatory) - Live option chains for NKTX/RCKT not confirmed — strike and pricing placeholders only. - Real-time prices and recent price action may be stale; verify before sizing. - Charts (price history, comp tables, capital structure, payoff diagrams) not rendered — user must add. - Capital structure / debt schedule / maturity wall not pulled for CRSP, NKTX, RCKT. - Insider transactions / 13D-13G not searched. - NKTX Ntrust-1/Ntrust-2 catalyst dates should be cross-checked against company IR calendar. - RCKT Danon Phase 2 update date is 2H 2026 — exact medical-conference date TBC. - Verve Therapeutics (VERV) was screened as a candidate but disqualified — acquired by Eli Lilly June 17, 2025, no longer tradeable. --- ## Related - Skill applied: `io-macro-idea-screening` (lives at `~/.hermes/skills/finance/io-macro-idea-screening/`, not in vault) - Standard trade-doc templates: `_templates/thesis.md`, `_templates/postmortem.md` - Standard location for future trade docs: `02-trades/` (this Files/ placement is exception)